8 completed, 3 terminated. 11 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 8, Terminated 3 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow Vascular Fistula: new trials by email Literature Review of Vascular Fistula trials Research Report on Vascular Fistula
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation PEG-liposomal prednisolone sodium phosphate, Placebo - Renal Dialysis, Hemodynamics | Phase 2 | Terminated | Leiden University Medical Center | 30 | 2015-11-01 | 2018-09-18 |
| Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access Vorapaxar sulfate, Placebo - AV Fistula | Phase 2 | Completed | Ken Mahaffey | 17 | 2015-08-26 | 2019-01-14 |
| An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access SRM003, Participating Site's standard practice - Arteriovenous Fistula | Phase 2 | Completed | Shire | 64 | 2013-03-26 | 2021-06-08 |
| Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula Rosuvastatin - End-stage Kidney Disease, Diabetes Mellitus | Phase 2 | Completed | National Cheng-Kung University Hospital | 60 | 2012-11-01 | 2019-02-19 |
| Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae Venous Window Needle Guide - End Stage Renal Disease, AV Fistula | Phase 2 / Phase 3 | Completed | Vital Access Corp. | 54 | 2011-12-01 | 2016-06-03 |
| Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis Heparin 2,400 IU /ml Cutaneous Spray, Placebo Cutaneous Spray - Haemodialysis | Phase 2 | Terminated | Cyathus Exquirere Pharmaforschungsgmbh | 30 | 2011-07-01 | 2014-05-08 |
| A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease PRT-201, Placebo - Chronic Kidney Disease | Phase 2 | Completed | Proteon Therapeutics | 151 | 2011-03-01 | 2015-04-30 |
| Reducing Hemodialysis Catheter Use in Prevalent Hemodialysis Patients Protocolized approach to convert dialysis catheter to fistula - Hemodialysis | Phase 2 | Terminated | Dr. Lisa Miller | 3 | 2009-02-01 | 2014-04-17 |
| A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients PRT-201 - Chronic Kidney Disease | Phase 1 / Phase 2 | Completed | Proteon Therapeutics | 66 | 2008-11-01 | 2015-04-30 |
| Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use Vascugel, Placebo Comparator - Hemodialysis Access | Phase 1 / Phase 2 | Completed | Pervasis Therapeutics, Inc | 65 | 2006-07-01 | 2011-10-27 |
| A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. AQUAVAN® (fospropofol disodium) Injection - Procedural Sedation | Phase 2 / Phase 3 | Completed | Eisai Inc. | 123 | 2006-05-01 | 2012-06-20 |
Arteriovenous Fistula (11) · Kidney Failure, Chronic (3) · Renal Insufficiency, Chronic (3) · Fistula (2) · Bunion (1) · Diabetes Mellitus (1) · Dilatation, Pathologic (1) · Neointima (1) · Renal Insufficiency (1) · Vascular Remodeling (1) · Vascular System Injuries (1)
Arteriovenous Malformations (11) · Cardiovascular Abnormalities (11) · Cardiovascular Diseases (11) · Congenital Abnormalities (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Pathological Conditions, Anatomical (11) · Pathological Conditions, Signs and Symptoms (11) · Vascular Diseases (11) · Vascular Malformations (11) · Fistula (9) · Pathologic Processes (7) · Chronic Disease (6) · Disease Attributes (6) · Female Urogenital Diseases (6)
cholesterol-binding protein (2) · Gelatin Sponge, Absorbable (1) · Heparin (1) · Injections (1) · Rosuvastatin Calcium (1) · fospropofol (1) · vorapaxar (1)
Proteon Therapeutics (2) · Cyathus Exquirere Pharmaforschungsgmbh (1) · Dr. Lisa Miller (1) · Eisai Inc. (1) · Ken Mahaffey (1) · Leiden University Medical Center (1) · National Cheng-Kung University Hospital (1) · Pervasis Therapeutics, Inc (1) · Shire (1) · Vital Access Corp. (1)
United States (7) · Austria (1) · Canada (1) · Netherlands (1) · Taiwan (1)
James B Jones, MD, PharmD (1) · Joris I Rotmans, MD PhD (1) · Jun-Neng Roan, MD, PhD (1) · Kenneth W Mahaffey, MD (1) · Lisa M Miller, MD (1) · Mark Crawford, BA (1) · Matthew W Mell, MD, MS (1)